Rainer König

Prof. Dr. Rainer König


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2014 in Bioinformatics
Verified
Journal Article
Open access
PDF file
TSTheresa Schacht
Theresa Schacht
MOMarcus Oswald
Marcus Oswald
RERoland Eils
Roland Eils
Stefan EichmüllerStefan Eichmüller
Stefan Eichmüller
RKRainer König
Rainer König
Motivation: Understanding regulation of transcription is central for elucidating cellular regulation. Several statistical and mechanistic models have come up the last couple of years explaining gene transcription levels using information of potential transcriptional regulators as transcription factors (TFs) and information from epigenetic modifications. The activity of TFs is often inferred by their transcription levels, promoter binding and epigenetic effects. However, in principle, these methods do not take hard-to-measure influences such as post-transcriptional modifications into account. Results: For TFs, we present a novel concept circumventing this problem. We estimate the regulatory activity of TFs using their cumulative effects on their target genes. We established our model using expression data of 59 cell lines from the National Cancer Institute. The trained model was applied to an independent expression dataset of melanoma cells yielding excellent expression predictions and elucidated regulation of melanogenesis. Availability and implementation: Using mixed-integer linear programming, we implemented a switch-like optimization enabling a constrained but optimal selection of TFs and optimal model selection estimating their effects. The method is generic and can also be applied to further regulators of transcription. Contact:rainer.koenig@uni-jena.de Supplementary information: Supplementary data are available at Bioinformatics online.

10 September 2020 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
EAEunice Oluwatobiloba Adedeji
Eunice Oluwatobiloba Adedeji
Olubanke OgunlanaOlubanke Ogunlana
Olubanke Ogunlana
SFSegun Fatumo
Segun Fatumo
TBThomas Beder
Thomas Beder
YAYvonne Ajamma
Yvonne Ajamma
EAEzekiel Adebiyi
Ezekiel Adebiyi
The increasing resistance to currently available insecticides in the malaria vector, Anopheles mosquitoes, hampers their use as an effective vector control strategy for the prevention of malaria transmission. Therefore, there is need for new insecticides and/or alternative vector control strategies, the development of which relies on the identification of possible targets in Anopheles. Some known and promising targets for the prevention or control of malaria transmission exist among Anopheles metabolic proteins. This review aims to elucidate the current and potential contribution of Anopheles metabolic proteins to malaria transmission and control. Highlighted are the roles of metabolic proteins as insecticide targets, in blood digestion and immune response as well as their contribution to insecticide resistance and Plasmodium parasite development. Furthermore, strategies by which these metabolic proteins can be utilized for vector control are described. Inhibitors of Anopheles metabolic proteins that are designed based on target specificity can yield insecticides with no significant toxicity to non-target species. These metabolic modulators combined with each other or with synergists, sterilants, and transmission-blocking agents in a single product, can yield potent malaria intervention strategies. These combinations can provide multiple means of controlling the vector. Also, they can help to slow down the development of insecticide resistance. Moreover, some metabolic proteins can be modulated for mosquito population replacement or suppression strategies, which will significantly help to curb malaria transmission.

1 January 2020 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
OAOlufemi Aromolaran
Olufemi Aromolaran
TBThomas Beder
Thomas Beder
MOMarcus Oswald
Marcus Oswald
JOJelili Oyelade
Jelili Oyelade
EAEzekiel Adebiyi
Ezekiel Adebiyi
RKRainer König
Rainer König
Genes are termed to be essential if their loss of function compromises viability or results in profound loss of fitness. On the genome scale, these genes can be determined experimentally employing RNAi or knockout screens, but this is very resource intensive. Computational methods for essential gene prediction can overcome this drawback, particularly when intrinsic (e.g. from the protein sequence) as well as extrinsic features (e.g. from transcription profiles) are considered. In this work, we employed machine learning to predict essential genes in Drosophila melanogaster. A total of 27,340 features were generated based on a large variety of different aspects comprising nucleotide and protein sequences, gene networks, protein-protein interactions, evolutionary conservation and functional annotations. Employing cross-validation, we obtained an excellent prediction performance. The best model achieved in D. melanogaster a ROC-AUC of 0.90, a PR-AUC of 0.30 and a F1 score of 0.34. Our approach considerably outperformed a benchmark method in which only features derived from the protein sequences were used (P < 0.001). Investigating which features contributed to this success, we found all categories of features, most prominently network topological, functional and sequence-based features. To evaluate our approach we performed the same workflow for essential gene prediction in human and achieved an ROC-AUC = 0.97, PR-AUC = 0.73, and F1 = 0.64. In summary, this study shows that using our well-elaborated assembly of features covering a broad range of intrinsic and extrinsic gene and protein features enabled intelligent systems to predict well the essentiality of genes in an organism.

30 October 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
VAVolker Ast
Volker Ast
TKTheresa Kordaß¹
Theresa Kordaß¹
MOMarcus Oswald
Marcus Oswald
AKAmol Kolte
Amol Kolte
DEDavid Eisel
David Eisel
RKRainer König
Rainer König
MiR-192, miR-200c and miR-17 are fibroblast-mediated inhibitors of colorectal cancer invasion MiR-192, miR-200c and miR-17 are fibroblast-mediated inhibitors of colorectal cancer invasion

29 February 2016 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
TKTheresa Kordaß¹
Theresa Kordaß¹
CWClaudia E. M. Weber
Claudia E. M. Weber
MOMarcus Oswald
Marcus Oswald
VAVolker Ast
Volker Ast
MBMathias Bernhardt
Mathias Bernhardt
RKRainer König
Rainer König
Melanoma is a cancer with rising incidence and new therapeutics are needed. For this, it is necessary to understand the molecular mechanisms of melanoma development and progression. Melanoma differs from other cancers by its ability to produce the pigment melanin via melanogenesis; this biosynthesis is essentially regulated by microphthalmia-associated transcription factor (MITF). MITF regulates various processes such as cell cycling and differentiation. MITF shows an ambivalent role, since high levels inhibit cell proliferation and low levels promote invasion. Hence, well-balanced MITF homeostasis is important for the progression and spread of melanoma. Therefore, it is difficult to use MITF itself for targeted therapy, but elucidating its complex regulation may lead to a promising melanoma-cell specific therapy. We systematically analyzed the regulation of MITF with a novel established transcription factor based gene regulatory network model. Starting from comparative transcriptomics analysis using data from cells originating from nine different tumors and a melanoma cell dataset, we predicted the transcriptional regulators of MITF employing ChIP binding information from a comprehensive set of databases. The most striking regulators were experimentally validated by functional assays and an MITF-promoter reporter assay. Finally, we analyzed the impact of the expression of the identified regulators on clinically relevant parameters of melanoma, i.e. the thickness of primary tumors and patient overall survival. Our model predictions identified SOX10 and SOX5 as regulators of MITF. We experimentally confirmed the role of the already well-known regulator SOX10. Additionally, we found that SOX5 knockdown led to MITF up-regulation in melanoma cells, while double knockdown with SOX10 showed a rescue effect; both effects were validated by reporter assays. Regarding clinical samples, SOX5 expression was distinctively up-regulated in metastatic compared to primary melanoma. In contrast, survival analysis of melanoma patients with predominantly metastatic disease revealed that low SOX5 levels were associated with a poor prognosis. MITF regulation by SOX5 has been shown only in murine cells, but not yet in human melanoma cells. SOX5 has a strong inhibitory effect on MITF expression and seems to have a decisive clinical impact on melanoma during tumor progression.

19 September 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
RKRainer König
Rainer König
XCXueqi Cao
Xueqi Cao
MOMarcus Oswald
Marcus Oswald
Christina BahrsChristina Bahrs
Christina Bahrs
GRGernot Rohde
Gernot Rohde
Mathias W. PletzMathias W. Pletz
Mathias W. Pletz
Background: The role of macrolide/β-lactam combination therapy in community-acquired pneumonia (CAP) of moderate severity is a matter of debate. Macrolides expand the coverage to atypical pathogens and attenuate pulmonary inflammation, but have been associated with cardiovascular toxicity and drug interactions. We developed a decision tree based on aetiological and clinical parameters, which are availableex anteto support a personalised decision for or against macrolides for the best clinical outcome of the individual patient.Methods: We employed machine learning in a cross-validation scheme based on a well-balanced selection of 4898 patients after propensity score matching to data available on admission of 6440 hospitalised patients with moderate severity (non-intensive care unit patients) from the observational, prospective, multinational CAPNETZ study. We aimed to improve the primary outcome of 180-day survival.Results: We found a simple decision tree of patient characteristics comprising chronic cardiovascular and chronic respiratory comorbidities as well as leukocyte counts in the respiratory secretion at enrolment. Specifically, we found that patients without cardiovascular or patients with respiratory comorbidities and high leukocyte counts in the respiratory secretion benefit from macrolide treatment. Patients identified to be treated in compliance with our treatment suggestion had a lower mortality of 27% (OR 1.83, 95% CI 1.48–2.27; p<0.001) compared to the observed standard of care.Conclusion: Stratifying macrolide treatment in patients following a simple treatment rule may lead to considerably reduced mortality in CAP. A future randomised controlled trial confirming our result is necessary before implementing this rule into the clinical routine.